Evidence map›Paper›PMID 40842344›Full record

ArticleBritish journal of pharmacology2025

Chronic Δ

Yasaman Razavi, Stephen J Kohut, Jack Bergman, Brian D Kangas

Abstract read
In one paragraph

Article in British journal of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yasaman RazaviHarvard Medical School, McLean Hospital, Belmont, Massachusetts, USA.
Stephen J KohutHarvard Medical School, McLean Hospital, Belmont, Massachusetts, USA.
Jack BergmanHarvard Medical School, McLean Hospital, Belmont, Massachusetts, USA.
Brian D KangasHarvard Medical School, McLean Hospital, Belmont, Massachusetts, USA.ORCID https://orcid.org/0000-0002-4597-9801

Funding

Neural, Cognitive and Abuse-Related Consequences of Chronic THC Exposure during Adolescence in Nonhuman PrimatesR01DA047575 · NIDA · MCLEAN HOSPITAL · PI JACK BERGMAN, Brian D. Kangas · 2019 to 2026
$5.7M
MDMA Mechanisms of Prohedonic Efficacy: A Reverse Translational ApproachR01MH136052 · NIMH · MCLEAN HOSPITAL · PI BLOUGH, BRUCE E, KANGAS, BRIAN D. · 2025 to 2025
$767k
NIDA NIH HHS R01 DA047575NIDA NIH HHS R01-DA047575NIMH NIH HHS R01 MH136052NIMH NIH HHS R01-MH136052
6 · The paper itself

Abstract

background and purposeLegalisation of Cannabis use has led to considerable increases in the availability and potency of Cannabis products, as well as evolving patterns in methods of their consumption. Adolescent Cannabis use has increased, which can impair cognitive function during this critical developmental stage. The persistence of such effects into adulthood, however, is unclear. The present study examined whether chronic Δ EXPERIMENTAL APPROACH: Female and male adolescent nonhuman primates were treated intramuscular daily for 6 months with either vehicle, a low dose of Δ KEY

resultsResults confirm dose-related Δ CONCLUSIONS AND IMPLICATIONS: These findings suggest a persistent impact of adolescent Δ

Indexed as

Behavior, AnimalDronabinolDrug ToleranceAnimalsDose-Response Relationship, DrugFemaleMaleDronabinoladolescenceattentional processesnonhuman primatestouchscreen cognitionΔ9‐tetrahydrocannabinol

Identifiers

PMID40842344
PMCPMC12882112

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.